Stem Cells and Cancer

Organized by Tannishtha Reya of the University of California, San Diego, Craig T. Jordan of the University of Colorado and Philip A. Beachy of HHMI/Stanford University, the four-day conference will:
• Focus on a developmental view of cancer, which holds enormous potential to expand our understanding of cancer initiation, metastasis, progression and therapy far beyond understandings and therapies based on the more traditional model of aberrant disease and death;
• Explore mechanisms driving the initiation and propagation of cancer, including the potential for normal stem cell signals active in development to be re-utilized during oncogenesis, the role of the cell of origin in the pathogenesis of cancer, and the role of cancer stem cells in cancer propagation;
• Bring together cancer and stem cell biologists, as well as clinicians, and provide even more opportunities for cross-disciplinary collaboration through the unique pairing with the joint meeting on “Developmental Pathways: Wnt, Notch and Hedgehog.”

+ show speakers and program
Jürgen A. Knoblich, IMBA - Institute of Molecular Biotechnology, Austria
Asymmetric Division

Anjana Rao, La Jolla Institute for Allergy and Immunology, USA
Methylation in Stem Cells and Cancer

Thea D. Tlsty, University of California, San Francisco, USA
Regulation of Mammary Stem Cells and Plasticity

Geoffrey M. Wahl, The Salk Institute, USA
Signaling in Mammary Stem Cells and Cancer

Xi He, Harvard Medical School, USA
Wnt Signaling Mechanism

Jeremy F. Reiter, University of California, San Francisco, USA
Hh Signaling in Cilia and Cancer

Raphael Kopan, Washington University, USA
Notch Signaling

Leonard I. Zon, HHMI/Children's Hospital Boston, USA
Stem Cells and Cancer in Model Organisms

Tannishtha Reya, University of California, San Diego, USA
Developmental Signaling in Stem Cells and Cancer

Elaine Fuchs, HHMI/Rockefeller University, USA
Signaling in Skin Stem Cells and Skin Cancer

Adolfo Ferrando, Columbia University, USA
T-ALL Therapeutics

Holger Gerhardt, London Research Institute, UK
Dll4/Notch Dynamics in Vascular Branching

Warren S. Pear, University of Pennsylvania, USA
Normal and Leukemogenic Roles for Notch in Immune Cells

Scott A. Armstrong, Memorial Sloan-Kettering Cancer Center, USA
Epigenetic Control of Myeloid Leukemia Development

Robert J. Wechsler-Reya, Sanford-Burnham Medical Research Institute, USA
Stem Cells and the Origins of Medulloblastoma

Philip A. Beachy, HHMI/Stanford University, USA
The Cellular Origin of Bladder Neoplasia and Tissue Dynamics of its Progression to Invasive Carcinoma

Luis F. Parada, University of Texas Southwestern Medical Center, USA
Lineage Tracing and the Cancer Initiating Cell in Brain Tumors

Jon C. Aster, Brigham and Women's Hospital, USA
Determinants of Notch Target Gene Activation in Cancer Cells

Stephen C. Blacklow, Dana Farber Cancer Institute, USA
Ligand-Mediated Notch Activation

Mariann Bienz, MRC Laboratory of Molecular Biology, UK
Nuclear Wnt Signaling

Marian Waterman, University of California, Irvine, USA
LEF/TCF Targets and Cancer Metabolism

Robert S. Kerbel, Sunnybrook Research Institute, Canada
Preclinical Models

Sean J. Morrison, HHMI/University of Texas Southwestern Medical Center, USA
The Regulation of Melanoma Metastasis

John E. Dick, Princess Margaret Cancer Centre, University Health Network, Canada
Leukemia Stem Cells

Jeffrey M. Rosen, Baylor College of Medicine, USA
Tracking and Targeting Breast Cancer Stem Cells

Freddy Radtke, EPFL SV ISREC UPRAD, Switzerland
Tumor Suppressive Roles of Notch in Epithelial Cells

Owen J. Sansom, Beatson Institute of Cancer Research, UK
Wnt and mTOR Signaling in the Intestine

Rune C-M. Toftgard, Karolinska Institutet, Sweden
Hedgehog Signaling, Stem Cells and Skin Cancer Initiation

Cédric Blanpain, Université Libre de Bruxelles, Belgium
Keynote Address: Tumor Stem Cells

Irving L. Weissman, Stanford University School of Medicine, USA
Keynote Address: Re-Engaging the Immune System against Cancer Stem Cells

Richard J. Gilbertson, St. Jude Children's Research Hospital, USA
Matching Therapy with Cancer in Developing Tissues

Roeland Nusse, HHMI/Stanford University, USA
Wnt Signaling in Development and Cancer

Catriona H.M. Jamieson, University of California, San Diego, USA
Therapeutic Targeting of Cancer Stem Cells in Hematologic Malignancies

Zena Werb, University of California, San Francisco, USA
Imaging the Microenvironment in Mammary Development and Cancer

Jing Yang, University of California, San Diego, USA
Epithelial-Mesenchymal Transition in Tumor Metastasis

Joan Massagué, HHMI/Memorial Sloan-Kettering Cancer Center, USA
Stem Cell Signals in Metastasis

Michael D. Taylor, Hospital for Sick Children, Canada
Hh in Medulloblastoma

Kimberly Stegmaier, Dana-Farber Cancer Institute, USA
Targeting Mutated NOTCH1 in Cancer

Joerg Huelsken, EPFL, Switzerland
Wnt-Dependent Metastasis

Charlotte Kuperwasser, Tufts University School of Medicine, New England, USA
Genetic and Epigenetic Plasticity of Stem Cells in Breast Cancer

Lewis A. Chodosh, University of Pennsylvania School of Medicine, USA
Mechanisms Controlling Dormancy and Tumor Recurrence

Vishva M. Dixit, Genentech, Inc., USA
Apoptosis and Cancer

Richard A. Lang, Cincinnati Children's Hospital Medical Center, USA
Wnt in Angiogenesis

Feng Cong, Novartis Institutes for BioMedical Research, USA
Control of Wnt Signaling by Ubiquitin and Tankyrase

Austin Gurney, OncoMed Pharmaceuticals, USA
Notch/Wnt Inhibitors in Tumor Stem Cells/Angiogenesis

Bradley E. Bernstein, Massachusetts General Hospital, Harvard Medical School, USA
Epigenetic Mechanism of Resistance to GSI

Craig T. Jordan, University of Colorado, Anschutz Medical Campus, USA
Therapeutic Targeting of Leukemia Stem Cells

Jeremy N. Rich, Cleveland Clinic, USA
Brain Tumor Stem Cells and Resistance to Therapy

Michael F. Clarke, Stanford University, USA
Targeting Cancer Stem Cells in Breast Cancer

Gavin O. Thurston, Regeneron Pharmaceuticals Inc., USA
Dll4 Inhibitor in Tumor Angiogenesis

Jean Y. Tang, Stanford University School of Medicine, USA
Hedgehog Pathway Inhibitor Clinical Trials

Frederic J. de Sauvage, Genentech, Inc., USA
Innate and Acquired Resistance to Hedgehog Pathways Inhibitors

2 Feb - 7 Feb 2014
meeting website